Lerch Thomas F, Sharpe Penelope, Mayclin Stephen J, Edwards Thomas E, Lee Eunhee, Conlon Hugh D, Polleck Sharon, Rouse Jason C, Luo Yin, Zou Qin
a Analytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc. , Chesterfield , MO , USA.
b Analytical Research and Development, Biotherapeutics Pharmaceutical Sciences, Pfizer Inc. , Andover , MA , USA.
MAbs. 2017 Jul;9(5):874-883. doi: 10.1080/19420862.2017.1320463. Epub 2017 Apr 19.
Aggregation and self-association in protein-based biotherapeutics are critical quality attributes that are tightly controlled by the manufacturing process. Aggregates have the potential to elicit immune reactions, including neutralizing anti-drug antibodies, which can diminish the drug's efficacy upon subsequent dosing. The structural basis of reversible self-association, a form of non-covalent aggregation in the native state, is only beginning to emerge for many biologics and is often unique to a given molecule. In the present study, crystal structures of the infliximab (Remicade) Fc and Fab domains were determined. The Fab domain structures are the first to be reported in the absence of the antigen (i.e., tumor necrosis factor), and are consistent with a mostly rigid complementarity-determining region loop structure and rotational flexibility between variable and constant regions. A potential self-association interface is conserved in two distinct crystal forms of the Fab domain, and solution studies further demonstrate that reversible self-association of infliximab is mediated by the Fab domain. The crystal structures and corresponding solution studies help rationalize the propensity for infliximab to self-associate and provide insights for the design of improved control strategies in biotherapeutics development.
基于蛋白质的生物治疗药物中的聚集和自缔合是关键的质量属性,受到生产过程的严格控制。聚集体有可能引发免疫反应,包括中和抗药物抗体,这可能会降低后续给药时药物的疗效。可逆自缔合是天然状态下一种非共价聚集形式,其结构基础对于许多生物制品来说才刚刚开始显现,并且通常是特定分子所特有的。在本研究中,测定了英夫利昔单抗(类克)Fc和Fab结构域的晶体结构。Fab结构域结构是在不存在抗原(即肿瘤坏死因子)的情况下首次报道的,并且与大部分刚性的互补决定区环结构以及可变区和恒定区之间的旋转灵活性一致。一个潜在的自缔合界面在Fab结构域的两种不同晶体形式中是保守的,溶液研究进一步证明英夫利昔单抗的可逆自缔合是由Fab结构域介导的。晶体结构和相应的溶液研究有助于解释英夫利昔单抗自缔合的倾向,并为生物治疗药物开发中改进控制策略的设计提供见解。